JP2023549814A - 銅代謝関連疾患又は障害を治療する方法 - Google Patents

銅代謝関連疾患又は障害を治療する方法 Download PDF

Info

Publication number
JP2023549814A
JP2023549814A JP2023528431A JP2023528431A JP2023549814A JP 2023549814 A JP2023549814 A JP 2023549814A JP 2023528431 A JP2023528431 A JP 2023528431A JP 2023528431 A JP2023528431 A JP 2023528431A JP 2023549814 A JP2023549814 A JP 2023549814A
Authority
JP
Japan
Prior art keywords
subject
biological sample
copper
tetrathiomolybdate
lbc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549814A5 (https=
Inventor
ウェイ－ジアン パン，
マーク マ，
ブライアン メルツァー，
ユージーン スコット スウェンソン，
スコット エドワード モズリー，
ライアン ペルト，
アダム キックアロ，
アンゲル， ギレルモ デル
ハリーシュ チャマルティ，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2023549814A publication Critical patent/JP2023549814A/ja
Publication of JP2023549814A5 publication Critical patent/JP2023549814A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • G01N33/683—Total protein determination, e.g. albumin in urine involving metal ions
    • G01N33/6833—Copper, e.g. Folin-, Lowry-, biuret methods
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023528431A 2020-11-13 2021-11-12 銅代謝関連疾患又は障害を治療する方法 Pending JP2023549814A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063113516P 2020-11-13 2020-11-13
US63/113,516 2020-11-13
US202163242722P 2021-09-10 2021-09-10
US63/242,722 2021-09-10
PCT/US2021/059239 WO2022104135A1 (en) 2020-11-13 2021-11-12 Methods of treating copper metabolism-associated diseases or disorders

Publications (2)

Publication Number Publication Date
JP2023549814A true JP2023549814A (ja) 2023-11-29
JP2023549814A5 JP2023549814A5 (https=) 2024-10-18

Family

ID=78844761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528431A Pending JP2023549814A (ja) 2020-11-13 2021-11-12 銅代謝関連疾患又は障害を治療する方法

Country Status (5)

Country Link
US (1) US20230414654A1 (https=)
EP (1) EP4243806A1 (https=)
JP (1) JP2023549814A (https=)
CA (1) CA3172751A1 (https=)
WO (1) WO2022104135A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023023199A1 (en) * 2021-08-17 2023-02-23 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders
WO2023038909A1 (en) * 2021-09-07 2023-03-16 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders
WO2024162974A1 (en) * 2023-01-30 2024-08-08 Alexion Pharmaceuticals, Inc. Tetrathiomolybdic acid for use in treating copper metabolism-associated diseases or disorders (wilson disease)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019110619A1 (en) * 2017-12-04 2019-06-13 Wilson Therapeutics Ab Bis-choline tetrathiomolybdate for treating wilson disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220334135A1 (en) 2019-09-12 2022-10-20 Alexion Pharmaceuticals, Inc. Methods of measuring copper concentration in biological samples

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019110619A1 (en) * 2017-12-04 2019-06-13 Wilson Therapeutics Ab Bis-choline tetrathiomolybdate for treating wilson disease
JP2021505655A (ja) * 2017-12-04 2021-02-18 アレクシオン・ファーマ・インターナショナル・オペレーションズ・アンリミテッド・カンパニー ウィルソン病を治療するためのビスコリンテトラチオモリブデート

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
C DERRICK QUARLES JR; ET AL: "LC-ICP-MS METHOD FOR THE DETERMINATION OF "EXTRACTABLE COPPER" IN SERUM", METALLOMICS, vol. VOL:12, NR:9, JPN5024006058, 2020, GB, pages 1348 - 1355, ISSN: 0005726138 *
FRANCE WOIMANT; ET AL: "NEW TOOLS FOR WILSON'S DISEASE DIAGNOSIS: EXCHANGEABLE COPPER FRACTION", ANNALS OF TRANSLATIONAL MEDICINE, vol. VOL:7, NR:S2, JPN5024006055, April 2019 (2019-04-01), US, pages 70 - 1, ISSN: 0005726134 *
GUILLAUD OLIVIER; ET AL: "RELATIVE EXCHANGEABLE COPPER: A VALUABLE TOOL FOR THE DIAGNOSIS OF WILSON DISEASE", LIVER INTERNATIONAL, vol. VOL:38, NR:2, JPN5024006056, February 2018 (2018-02-01), GB, pages 350 - 357, ISSN: 0005726135 *
ROBERTS EVE A: "BIS-CHOLINE TETRATHIOMOLYBDATE IN PATIENTS WITH WILSON'S DISEASE: AN OPEN-LABEL, 以下備考", CURRENT GASTROENTEROLOGY REPORTS, vol. VOL:20, NR:12, JPN5024006054, 5 November 2018 (2018-11-05), pages 1 - 12, ISSN: 0005726133 *
SOULEIMAN EL BALKHI; ET AL: "RELATIVE EXCHANGEABLE COPPER: A NEW HIGHLY SENSITIVE AND HIGHLY SPECIFIC BIOMARKER 以下備考", CLINICA CHIMICA ACTA, vol. VOL:412, NR:23, JPN5024006057, 11 August 2011 (2011-08-11), NL, pages 2254 - 2260, ISSN: 0005726136 *
WEISS KARL HEINZ; ET AL: "BIS-CHOLINE TETRATHIOMOLYBDATE IN PATIENTS WITH WILSON'S DISEASE: AN OPEN-LABEL, 以下備考", THE LANCET - GASTROENTEROLOGY & HEPATOLOGY, vol. VOL:2, NR:12, JPN5024006053, 30 November 2017 (2017-11-30), US, pages 869 - 876, ISSN: 0005726137 *

Also Published As

Publication number Publication date
CA3172751A1 (en) 2022-05-19
EP4243806A1 (en) 2023-09-20
US20230414654A1 (en) 2023-12-28
WO2022104135A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
JP2023549814A (ja) 銅代謝関連疾患又は障害を治療する方法
US10884005B2 (en) Diabetes-related biomarkers and treatment of diabetes-related conditions
Rizwan et al. Preliminary analysis of the effect of Stevia (Stevia rebaudiana) in patients with chronic kidney disease (stage I to stage III)
KR102803161B1 (ko) 윌슨병을 치료하기 위한 비스-콜린 테트라티오몰리브데이트
Yang et al. Association of serum irisin and body composition with chronic kidney disease in obese Chinese adults: a cross-sectional study
Mu et al. Comparison of two regimens for patients with thyroid-associated ophthalmopathy receiving intravenous methyl prednisolone: a single center prospective randomized trial
Jia et al. A study on the status of normoalbuminuric renal insufficiency among type 2 diabetes mellitus patients: A multicenter study based on a Chinese population
Akaza et al. Clinical outcome of subclinical Cushing's syndrome after surgical and conservative treatment
Eshraghi et al. Risk Factors of COVID-19 associated mucormycosis in Iranian patients: a multicenter study
JP2024532131A (ja) 銅代謝関連疾患又は障害を治療する方法
Hosomi et al. The optimal timing of antihypertensive medication administration for morning hypertension in patients with cerebral infarction
Singh et al. Epidemiology and clinical characteristics of chronic kidney disease in Bihar: a cross-sectional study from a single center
CN116685334A (zh) 治疗铜代谢相关疾病或障碍的方法
Diniz et al. Metabolomic analysis of retinopathy stages and amputation in type 2 diabetes
Koike et al. Glomerular density-associated changes in clinicopathological features of minimal change nephrotic syndrome in adults
JP2024534936A (ja) 銅代謝関連疾患又は障害を治療する方法
Meng et al. Interaction analysis of systolic blood pressure and glycosylated hemoglobin in diabetic retinopathy: A Chinese sample
Li et al. Identification of biomarkers that predict renal flare in childhood-onset lupus nephritis with mycophenolate acid
Yang et al. Fasting plasma glucose levels predict steroid-induced abnormal glucose metabolism in patients with non-diabetic chronic kidney disease: a prospective cohort study
JP2026503721A (ja) 銅代謝関連疾患又は障害（ウィルソン病）の治療における使用のためのテトラチオモリブデン酸
US20240382435A1 (en) Non-ceruloplasmin bound copper level monitoring
Sinha et al. STUDY OF SERUM URIC ACID AND VITAMIN-D LEVELS IN PATIENTS WITH ESSENTIAL HYPERTENSION AT MGM MEDICAL COLLEGE, KISHANGANJ
CN117835989A (zh) 治疗铜代谢相关疾病或障碍的方法
Bhat et al. WCN25-1092 A STUDY OF CLINICOPATHOLOGICAL SPECTRUM AND OUTCOME OF PRIMARY MEMBRANOUS NEPHROPATHY
Anar et al. Idiopathic pulmonary fibrosis: What has changed in the diagnosis and treatment from past to present?

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260406